From Nova Scotia to the Forefront of Bio & Tech Investing: Julie Sunderland of Biomatics on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Fighting Cancer With Food and Drugs: Lew Cantley and Sid Mukherjee on The Long Run
Structural Biology-Driven Drug Discovery: Ray Stevens on The Long Run
Making Clinical Trials More Diverse: Michele Andrasik on The Long Run
Rethinking the Cell Therapy Business: Derrell Porter of Cellevolve on The Long Run